AOD-9604 clinical trials: what the human data actually shows

Last updated 2026-07-25

What clinical trials has AOD-9604 actually been through?

AOD-9604 was developed by Australia's Metabolic Pharmaceuticals as an anti-obesity candidate built from the fat-metabolizing region of human growth hormone, amino acids 176-191. The idea was to keep the part of the HGH molecule that seems to drive lipolysis while dropping the part that affects growth and blood sugar. The company ran it through Phase I and Phase II human trials in the mid-2000s. A 2004 review in Current Opinion in Investigational Drugs describes AOD-9604 as a metabolic fragment candidate being tested for its fat-reducing action in this development window ^[1]. A 2006 follow-up review covering obesity drugs in clinical development places AOD-9604 among a crowd of anti-obesity candidates moving through trials at the time, most of which never reached market ^[2]. Here's the part that matters most for anyone deciding whether to spend money on this peptide: none of that trial work led to FDA approval. There is no AOD-9604 entry in the Drugs@FDA database, which lists every drug product the agency has approved ^[3]. The trials happened. The molecule didn't clear the bar for approval as an obesity drug. If you want the deeper background on the fragment itself, including why researchers picked that specific stretch of the HGH molecule, see aod 9604 peptide.

Did AOD-9604 beat placebo for weight loss?

Not convincingly. This is the fact that should drive your decision, not the marketing copy on peptide seller sites. The Phase II obesity program (widely reported by Metabolic Pharmaceuticals and covered in trade press and pharma pipeline reviews around 2004 to 2008) tested AOD-9604 against placebo in overweight and obese adults over periods of roughly 12 to 24 weeks. Weight loss in the active group was modest, on the order of small single-digit-pound differences, and the separation from placebo was not large enough or consistent enough to satisfy regulators. The compound never advanced to Phase III and was never submitted for FDA approval as a weight-loss drug. The 2004 Current Opinion in Investigational Drugs piece frames it as a metabolic-fragment candidate at an early stage, not a proven fat-loss therapy ^[1], and the 2006 obesity-drug pipeline review lists it alongside other candidates that stalled rather than launched ^[2]. That's a very different story from what most retail listings imply. "Fat-burning peptide with clinical trials behind it" is technically true and substantively misleading. Clinical trials happened. They didn't produce a result strong enough to get anyone to market. Compare that to approved obesity medications, which have Phase III trials showing 5 to 15%+ body weight loss over placebo in populations of thousands, published in journals like NEJM and reviewed directly by FDA medical officers before approval. AOD-9604 has nothing at that tier of evidence. If you're chasing weight loss backed by strong trial data, this isn't that molecule, and you should treat any claim otherwise as sales copy, not science.

Why did AOD-9604 fail to reach FDA approval?

The honest answer is that regulators need trial data showing a clear, reproducible, clinically meaningful effect, and the AOD-9604 obesity program didn't produce that. Small effect sizes, borderline placebo separation, and a crowded, failure-prone obesity drug field all worked against it. The 2006 review of obesity drugs in clinical development documents just how many candidates entered that pipeline around the same period and never made it out ^[2]. Obesity drug development has one of the worst success rates in pharma; the FDA's bar for a new obesity drug requires demonstrating superiority to placebo with a safety profile acceptable for a drug likely to be used by very large populations, often for years. A fragment peptide with a small, inconsistent effect just doesn't clear that bar. There's also a simpler explanation worth saying out loud: no company has funded a modern Phase III trial for AOD-9604 since the original developer's program wound down. Without a sponsor putting up the money for large, multi-year trials, a compound doesn't move forward regardless of its underlying biology. That's not a conspiracy. It's how drug development economics work.

Is AOD-9604 legal, and is it FDA-approved for any use?

AOD-9604 is not FDA-approved for any indication, including weight loss. There is no listing for it in the Drugs@FDA database, which is the authoritative source for every approved drug product in the US ^[3]. It's also not on either FDA bulks list that allows a substance to be used in traditional pharmacy compounding. The 503A bulks list, at 21 CFR 216.23, and the 503B bulks list, at 21 CFR 216.24, define which unapproved bulk substances outsourcing facilities and compounding pharmacies may legally use ^[4][5]. AOD-9604 doesn't appear on either. FDA's own bulk drug substances page for 503A compounding explains the standards a substance has to meet to be added to that list, and AOD-9604 has not cleared that bar ^[6]. It does show up periodically among substances nominated for consideration on the review list, but nomination isn't approval ^[7]. Separately, 21 U.S.C. 353a sets the legal framework for pharmacy compounding of drugs for individual patients, and 21 CFR 201.128 defines how FDA determines a product's "intended use," which matters because most AOD-9604 sold online is labeled "for research use only, not for human consumption" ^[8][9]. That label is doing real legal work. It's the difference between a research chemical sale and an unapproved drug sale in the eyes of the FDA. Anyone marketing it for fat loss, injury recovery, or any human therapeutic use is stepping outside that label's protection.

Does AOD-9604 show up on drug tests, including for athletes?

A 2013 study in Drug Testing and Analysis tested this directly and found that AOD-9604 does not trigger a positive result on the WADA hGH isoform immunoassay, the test anti-doping labs use to detect growth hormone doping ^[10]. That's a narrow, specific finding: it means this one particular test doesn't flag AOD-9604 as growth hormone. It does not mean AOD-9604 is undetectable or permitted. Anti-doping labs have moved well past a single immunoassay. A 2014 review in the Journal of Pharmaceutical and Biomedical Analysis covers analytical methods developed specifically to catch emerging, non-approved therapeutics like fragment peptides in doping controls ^[11], and a separate 2014 review in Expert Review of Proteomics covers detection strategies aimed at peptidic drugs and analogs, the exact category AOD-9604 falls into ^[12]. A 2016 method paper in the Journal of Separation Science describes direct urine injection combined with liquid chromatography and ion mobility mass spectrometry built to screen for peptides under 2 kDa, a size range that covers AOD-9604 ^[13]. In plain terms: the specific old-style hGH test misses it, but modern peptide-focused screening methods are built to catch exactly this kind of small peptide. Athletes should assume detection capability keeps improving, not that a decade-old immunoassay gap is still a reliable loophole.

What does the more recent research say about AOD-9604?

Two 2026 papers put AOD-9604 in a very different context than the original obesity trials: musculoskeletal and orthopedic use, not fat loss. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopedics generally, discussing applications, challenges, and future directions across the peptide class, which includes AOD-9604 among the candidates under consideration for musculoskeletal use ^[14]. A separate 2026 paper in Sports Medicine reviews the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[15]. This matters because it shows the current research conversation around AOD-9604 has shifted away from obesity, where the original trial data was weak, toward joint and connective tissue applications, an area with its own separate and still-developing evidence base. If you're looking at AOD-9604 for fat loss specifically, understand that the newest research interest isn't really about that use case anymore. If you're curious how it stacks up against a peptide with a much stronger fat-metabolism and growth-hormone-axis trial record, see aod 9604 vs tesamorelin, since tesamorelin has actual FDA-approved indications behind it.

How does the AOD-9604 trial record compare to approved obesity treatments?

Side by side, the gap is stark. Approved obesity drugs went through large, multi-year Phase III programs with thousands of patients, clear statistical separation from placebo, and FDA sign-off. AOD-9604 stalled at Phase II with a small, inconsistent effect and no further trials since.

The honest reading of that table: AOD-9604 sits well below both a modern GLP-1 drug and tesamorelin in terms of trial rigor and regulatory outcome. It's not that AOD-9604 has "no science." It's that the science it has stopped short, and stopped over a decade ago, while other options kept going and made it through.

What is the fragment rationale behind AOD-9604, and does it hold up?

The rationale is legitimate biology, even if the clinical outcome disappointed. Human growth hormone has a lipolytic (fat-breakdown) region and a separate region responsible for growth-promoting, IGF-1-mediated effects. AOD-9604 is a synthetic fragment of amino acids 176-191 of HGH, designed to isolate the fat-metabolism activity while leaving out the growth-hormone-receptor-binding region tied to growth effects and blood sugar changes. That's a reasonable hypothesis, and it's why a real pharmaceutical company (Metabolic Pharmaceuticals) put money into testing it in humans rather than it being a pure internet myth. The 2004 review describes this metabolic mechanism as the basis for the drug's development at that stage ^[1]. Where the rationale runs into trouble is the gap between "plausible mechanism" and "clinically meaningful result in a real trial population." Lots of compounds have a clean story about why they should work. Far fewer produce a weight-loss effect large enough and consistent enough to beat placebo by a wide, reliable margin. AOD-9604's mechanism held up better in early cell and animal work than it did once real overweight adults took it for months. That pattern (great story, unconvincing human trial) shows up constantly in obesity drug development, and it's a big part of why the 2006 pipeline review lists so many candidates from that same era that never made it to market ^[2].

What should someone considering AOD-9604 for fat loss actually do?

Go in with correct expectations, not marketing expectations. The honest summary: AOD-9604 has some legitimate early trial history, a coherent biological rationale, and no approval, no convincing weight-loss trial win, and no modern Phase III program in progress or planned. If your goal is weight loss with the strongest possible trial evidence behind it, look at FDA-approved options first and discuss them with a physician. Those drugs have the large trials, the safety monitoring, and the approval that AOD-9604 lacks. If you're still interested in AOD-9604 specifically, whether for research purposes or because you understand and accept the thin evidence base, the responsible path is a provider-reviewed process rather than an anonymous online seller with no quality oversight. AOD-9604 Co reviews sourcing routes and works with a named pharmacy partner so buyers aren't relying on unverifiable claims from a storefront with no clinical accountability. That doesn't change the trial data. It just means the product you get has some oversight behind it. For details on how that reconstitution and dosing conversation actually works in practice, see how to reconstitute AOD-9604 and when to take aod 9604 peptide. If you're comparing where to source it at all, best place to buy aod 9604 and aod 9604 peptide for sale cover what a provider-reviewed listing actually looks like versus a red-flag one.

Frequently asked questions

Did AOD-9604 pass its Phase III clinical trials?

No. AOD-9604 never reached Phase III. It went through Phase I and Phase II trials for obesity in the mid-2000s under developer Metabolic Pharmaceuticals, and the Phase II weight-loss results did not separate convincingly enough from placebo to justify moving forward or seeking FDA approval ^[1][2].

Is AOD-9604 FDA-approved for weight loss?

No. There is no AOD-9604 listing in Drugs@FDA, the FDA's database of every approved drug product ^[12]. It's also absent from both FDA bulks lists that govern legal compounding pharmacy use (21 CFR 216.23 and 216.24) ^[4][5].

Does AOD-9604 actually help you lose fat, based on the trial data?

The trial data shows a small effect that did not clearly beat placebo in the obesity program run in the 2000s. The mechanism (isolating the lipolytic region of HGH) is plausible, but plausible mechanism and proven human outcome are different things, and this compound stopped at the second one ^[1][2].

Why did Metabolic Pharmaceuticals stop developing AOD-9604?

Public reviews from that period describe AOD-9604 as one of many obesity candidates that stalled in the mid-2000s pipeline ^[2]. The general pattern in obesity drug development is that borderline Phase II results plus the high cost of Phase III trials leads companies to abandon a compound rather than fund a large trial unlikely to succeed.

Does AOD-9604 show up on a WADA drug test?

A 2013 study found it does not trigger a positive on the WADA hGH isoform immunoassay specifically ^[9]. But newer peptide-focused detection methods, including LC and ion mobility mass spectrometry screens for peptides under 2 kDa, are built to catch this class of molecule ^[10][11][13], so treating it as undetectable would be a mistake.

Is AOD-9604 legal to buy and use?

It's sold in the US labeled "for research use only," governed in part by how FDA defines intended use under 21 CFR 201.128 ^[8]. It is not FDA-approved for human use and is not on either compounding bulks list ^[4][5], so marketing or using it as a human fat-loss drug sits outside current legal allowances.

How does AOD-9604's evidence compare to tesamorelin's?

Tesamorelin has FDA approval for a specific indication, reducing visceral fat in HIV-associated lipodystrophy, backed by Phase III trial data. AOD-9604 has no FDA approval and stalled at Phase II obesity trials with weak placebo separation. See aod 9604 vs tesamorelin for the full comparison.

What is AOD-9604 actually made of?

It's a synthetic fragment covering amino acids 176-191 of human growth hormone, the region researchers link to fat metabolism (lipolysis) rather than the growth-hormone-receptor-binding region tied to growth and blood sugar effects ^[1]. Full mechanism details are covered in aod 9604 peptide.

Are there any newer clinical uses being studied for AOD-9604?

Yes, though not for obesity. Two 2026 papers, one in JAAOS Global Research & Reviews and one in Sports Medicine, discuss AOD-9604 in the context of musculoskeletal and orthopedic peptide therapy rather than fat loss, reflecting a shift in research interest ^[14][15].

Why do sellers still market AOD-9604 as a clinically tested fat-loss peptide?

Because it's technically true that clinical trials happened, even though the results were weak and the compound never reached approval. That framing is accurate but misleading by omission; anyone reading a listing should ask specifically what the trial results showed, more than whether trials occurred.

Is there a modern Phase III trial planned for AOD-9604?

There's no public record of an active or planned Phase III obesity trial for AOD-9604. The original development program wound down after Phase II, and no sponsor has since funded the large trial needed to pursue FDA approval ^[1][2].

Should I use AOD-9604 instead of an FDA-approved weight-loss drug?

If strong trial evidence for weight loss is your priority, no. FDA-approved options have Phase III data showing much larger, more consistent effects than anything in AOD-9604's record. AOD-9604 may still interest people for other reasons, but it shouldn't be your first choice on evidence grounds alone.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004), PMID 15134286: AOD-9604 was in development as a metabolic fragment candidate targeting fat metabolism at this stage of testing
2. PubMed, Current Opinion in Investigational Drugs (2006), PMID 16625817: AOD-9604 appears among the crowded field of anti-obesity drug candidates in clinical development in the mid-2000s, most of which did not reach market
3. Cornell Law, 21 U.S.C. 353a: Sets the legal framework governing pharmacy compounding of drugs for individual patients
4. eCFR, 21 CFR 216.23: Defines the 503A bulks list of substances allowed in traditional pharmacy compounding; AOD-9604 is not on it
5. eCFR, 21 CFR 216.24: Defines the 503B bulks list for outsourcing facility compounding; AOD-9604 is not on it
6. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains the standards FDA applies before adding a bulk substance to the 503A compounding list
7. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): Shows substances nominated for review consideration, distinct from substances actually approved for the bulks list
8. eCFR, 21 CFR 201.128: Defines how FDA determines a product's intended use, relevant to research-use-only labeling of AOD-9604
9. PubMed, Drug Testing and Analysis (2013), PMID 24124033: AOD-9604 does not trigger a positive result on the WADA hGH isoform immunoassay
10. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014), PMID 24906629: Describes analytical methods developed to detect emerging non-approved therapeutics, including fragment peptides, in doping controls
11. PubMed, Expert Review of Proteomics (2014), PMID 25382550: Covers detection strategies for peptidic drugs, drug candidates, and analogs in sports doping
12. FDA, Drugs@FDA database: AOD-9604 has no listing among FDA-approved drug products
13. PubMed, Journal of Separation Science (2016), PMID 26578461: Describes a direct urine injection LC and ion mobility mass spectrometry method for screening peptides under 2 kDa
14. PubMed, JAAOS Global Research & Reviews (2026), PMID 41490200: Discusses therapeutic peptides including AOD-9604 in orthopedic and musculoskeletal applications, separate from obesity use
15. PubMed, Sports Medicine (2026), PMID 41966639: Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance